SIGA Technologies to Discuss Year-End 2008 Results of Operations On March 12, 2009

NEW YORK, March 9, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NasdaqCM:SIGA - News), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, plans to discuss its year-end 2008 results in a press release that will be issued on Thursday, March 12, 2009 before the market open.

The Company has scheduled a conference call and simultaneous webcast to discuss the results at 10:00 am EDT on Thursday, March 12, 2009. The Company will also discuss the recent presolicitation announcement by BARDA concerning acquisition of a smallpox therapeutic on the call.

Participants should call 877-741-4248 (United States/Canada) or 719-325-4750 (International) and request the SIGA Technologies call or utilize the confirmation code 4232923. A live broadcast of the earnings conference call will also be available via the Internet at http://www.SIGA.com. During the call, there will be a question-and-answer session open to analysts and institutional investors. The Company will also take a limited number of questions by email at info@siga.com. The deadline for submitting questions is Wednesday, March 11, 2009 at 3:00 pm ET.

If you are unable to participate, an audio replay of the call will be available beginning two hours after the call and will be available until 11:59 p.m. on Tuesday, March 24, 2009, by dialing 888-203-1112 (domestic) or 719-457-0820 (international) using replay pass code 4232923. The webcast of the event will also be archived on the Company's website for one year.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's Web site at http://www.siga.com/.

The SIGA Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4504

          KCSA Strategic Communications
          Todd Fromer
            212-896-1215
            Tfromer@kcsa.com
          Marybeth Csaby
            212-896-1236
            mcsaby@kcsa.com